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Adherence to taking medication is essential for patients with chronic diseases such as Type 2
Diabetes Mellitus (T2DM). There have been many studies about the association between medication
adherence and HbA1c levels, but few have used Adherence Refills and Medications Scale (ARMS)
questionnaire and Proportion of Days Covered (PDC) method to measure adherence in Indonesian
population. The aim of this study were to assess the association of medication adherence to HbA1c
levels and compare two methods of adherence measurements. This research was conducted at Pasar
Minggu Public Health Center, Jakarta using a cross-sectional design. The adherence assessment
was conducted using a validated Indonesian version of the ARMS questionnaire and compared
to the pharmacy refill adherence method using the PDC calculation. One hundred twenty-seven
T2DM patients (75.6% female) with mean age of 58.69 years were recruited. The proportion of
adhere patients as measured by ARMS was only 39.4% (50/127). Meanwhile, the proportion of
adhere patients as measured by PDC was 77.2% (98/127). Adherence by both measurement showed
significant associations with HbA1c <7% (ARMS, OR 4.000 (95% CI 1.705 – 9.386), p = 0.002;
PDC, OR 5.674 (95% CI 1.266 – 25.438), p = 0.024). After controlled by covariates, the result
remained significant (ARMS, aOR 4.281 (95% CI 1.785 – 10.267, p = 0.001; PDC, aOR 5.83 (95%
CI 1.287 – 26.405), p = 0.022). Adherence and HbA1c levels was significantly associated even after
controlling covariates. ARMS and PDC generated different proportions of adhere patients and may
indicate the need of combining the two methods in measuring adherence.
Keywords: diabetes mellitus; medication adherence; adherence refills and medications scale;
proportion of days covered; HbA1c
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INTRODUCTION
Around 537 million adults aged 20-79 years are living
with diabetes mellitus (DM). Type 2 Diabetes Mellitus
(T2DM) sufferers have the highest rate (more than
90%) compared to other types of DM worldwide
(International Diabetes Federation, 2021). T2DM is a
non-communicable disease that requires special attention
because it causes death and severe complications such
as chronic heart disease, cerebrovascular disease,
peripheral vascular disease, retinopathy, nephropathy
and neuropathy (Nanayakkara et al., 2021).
The effectiveness of the therapeutic regimen highly
depends on medication adherence (Anghel et al., 2019).
There have been many research investigating the effect
of adherence to clinical outcomes. Poor adherence has
serious consequences such as failure of therapy (AlHassany et al., 2019) and contribute to complications
and even death (Lomper et al., 2018). Besides that, nonadherent patients also require a higher number of health
care compared to adherent patients (Ye et al., 2022). In
the case of DM, adherence to taking medication helps

patients with DM to achieve the expected target blood
sugar levels (Nichols et al., 2016). Therefore, it is
necessary to carry out routine adherence assessments in
the DM population.
Generally, the widely used biological marker in DM is
HbA1c (Gupta et al., 2017). HbA1c provides a reliable
measure of chronic glycemia and correlates with longterm risk of diabetic complications (Sherwani et al.,
2016). Therefore, HbA1c is an important indicator of
long-term glycemic control reflecting the cumulative
glycemic history in the previous two to three months
(Sherwani et al., 2016). HbA1c as a clinical outcome can
be reflective to a real condition of patients’ adherence.
Many research demonstrated that the decrease in HbA1c
values is in line with high patient adherence to treatment
(Krapek et al., 2004; Doggrell & Warot, 2014; Nichols et
al., 2016; Patel et al., 2019).
An accurate assessment of medication adherence is
necessary for effective and efficient treatment planning.
It is to ensure that changes in health outcomes are
linked to recommended regimens. However, there is no
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adherence measurement tool that is considered the most
ideal for T2DM patients. One measurement approach
is to ask patients to subjectively assess their adherence
behavior which is usually carried out with the help of
a questionnaire (World Health Organization, 2003), e.g.
Adherence Refill and Medication Scale (ARMS). Other
options are assessing adherence through pharmacy
records or monitoring electronic drug administration,
e.g. Proportion of Days Covered (PDC) (Anghel et al.,
2019). ARMS that has been validated and is a good
instrument to measure patients’ adherence, especially
in chronic diseases (Kripalani et al., 2009). Although
there have been many studies regarding the association
between medication adherence and HbA1c levels, few
have used the ARMS instrument as a tool to measure
adherence, particularly in the Indonesian population.
ARMS is considered newer instrument compare to other
tools like MPR, MMAS, PDC, etc (Morisky et al., 1986;
Avorn et al., 1998; Benner et al., 2002; Kripalani et al.,
2009). It has been translated into Bahasa Indonesia and
has a good validity and reliability (Cahyadi et al., 2015).
Therefore, this study aimed to assess the association
of adherence using ARMS questionnaire with HbA1c
levels. To confirm the result, the study also compared the
use of ARMS with PDC in measuring adherence. The
study is expected to ensure the impact of adherence and
offer good alternative in measuring adherence.
METHODS
Design
This research was an observational study with a crosssectional design. After obtaining permission from the
DKI Jakarta Provincial Health Office and the South
Jakarta Health Sub-department as well as approval
from the Ethics Committee of the Faculty of Medicine,
University of Indonesia, data were collected at the NonCommunicable Diseases Polyclinic, Pasar Minggu
Jakarta Primary Health Center. The ethical approval
number is KET-875/UN2.F1/ETIK/PPM.00.02/2021
Subjects and Data Collection
A total of 127 subjects were involved in this study.
Sample size was calculated using formula as follows
(Ogston et al., 1991):

Description:
Z1-α/2 = The standard normal deviation (5% for type 1
error (p<0.05) is 1.96)
Z1-β = The standard normal deviation for 80% power,
(20% for type 2 error is 0.842)
P = (P1+P2)/2
E-ISSN 2477-0612
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P1 = Proportion of patients with controlled blood
glucose in non-adherent group
P2 = Proportion of patients with controlled blood
glucose in adherent group
With a P1 value of 0.169 and a P2 value of 0.467
(Hammad et al., 2017), the minimum sample size was
38 subjects per group.
T2DM patients aged ≥ 36 years and able to communicate
well were included this study. This study also required
patients to be able to see, hear, speak and be able to read,
and write to participate in this research. Patients who had
been diagnosed with mental disorders, dementia, and had
psychiatric disorders such as depression based on the
Beck Depression Inventory-II (BDI-II) were excluded.
Patients who met the inclusion criteria above would fill
out the BDI-II Questionnaire to determine the patient’s
depression status. The BDI-II questionnaire consists
of 21 groups of statements in which each group has 4
options with a value of 0 to 3 points. Research subjects
were asked to choose the statement that best describes
their feelings during the last 2 weeks. The cut-off
value used was 17; subjects that had score below 17
were considered normal or no depression (Ginting et
al., 2013). Depression was excluded because it had a
high prevalence in T2DM patients (76%) (Abd Elaaty
et al., 2019) and is known to be associated with low
medication adherence (Grenard et al., 2011; Lunghi et
al., 2017). In addition, depressed patients tend to have
difficulty communicating with healthcare providers. In
fact, they often feel dissatisfied with the service they
receive because of the communication problem (Piette
et al., 2004). Patients who passed the BDI-II screening
were interviewed regarding their demographic data and
clinical condition. After that, the patient’s cognitive
function was assessed with the Indonesian version
of the Montreal Cognitive Assessment (MoCA-Ina)
questionnaire (Husein et al., 2010) with a cutoff value
of ≥26 to determine the patient has a normal cognitive
function (Nasreddine et al., 2005; Husein et al., 2010).
The study used HbA1c as the clinical outcome. Analysis
of peripheral blood samples to measure HbA1c levels
was directly carried out at Pasar Minggu Public Health
Center using the Alere AfinionTM tool. The HbA1c value
as a clinical outcome determines glycemic control status.
Blood glucose was considered controlled if the HbA1c
value was <7 (American Diabetes Association, 2014;
Abd Elaaty et al., 2019).
Adherence Measurement
The tools that were used to assess patient adherence
were ARMS questionnaire and PDC calculation. The
validated English ARMS questionnaire was translated
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into Bahasa Indonesia and had been tested in diabetes
population in three primary healthcare facilities.
(Cahyadi et al., 2015). Questionnaire validity and
reliability was considered good considering a correlation
value of >0.3 and Cronbach’s alpha of 0.815 (Cahyadi
et al., 2015). The Indonesian version of the ARMS
Questionnaire consisted of 11 questions, 8 questions
about correct medication behavior, and 3 questions about
timely refilling of prescription drugs. Each question
has 4 answer choices (Likert scale) namely “never”,
“sometimes”, “often”, or “every time”, which are scored
from 1 to 4. For the last question, the score is reversed to
make it consistent with other questions. The scores for
each question item are summed to produce an overall
adherence score. i.e. between 11 to 44. ARMS scores
over 11 are considered non-adhere (Cahyadi et al., 2015;
Kripalani et al., 2009).
To calculate the PDC value, data on patient drug intake
for the last 6 months through the e-puskesmas system
(electronic medical record) were obtained. PDC is the
percentage of the sum of days covered in a time frame
divided by number of days in time frame (Anghel et al.,
2019), which in this case the time frame was 180 days (6
months). ‘Days covered’ were days when patients have
the prescribed daily dose of medicine according to their
refill schedule. When patients were late refilling their
medicines, the days from their last pill to their next refill
were not included in the sum of days covered. PDC has
been widely used to measure adherence with some of
the earliest studies were conducted in late 90s (Avorn et
al., 1998; Benner et al., 2002). Patients were considered
adhered if the PDC value was 80% (Anghel et al., 2019).
Data Analysis
Association of adherence based on ARMS scores with
the HbA1c level was assessed. Measurement with
PDC was also performed to compare and confirm the
result. Univariate analysis was used to describe patients’
characteristics. In determining association between
adherence measurement and HbA1c values, chi-square
test was performed. P-value <0.05 was considered
significant. Logistic regression was conducted to identify
other factors that affect HbA1c level. Variables that had
p<0.25 in bivariate analysis and/or substantially affected
HbA1c were included in logistic regression. Comparison
of two adherence measurements were conducted by
analysing the proportion of adhere and non-adhere
patients. Data was expressed in proportion (n,%) for
categorical variables and in mean ± SD or median (minmax) for numeric variables.
RESULTS
A total of 127 T2DM patients participated in this
research. The majority of research subjects were
women with a mean age of 58 years. The proportion of
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patients with an education level of more than 12 years
and less than 12 years was almost equal (52.8% and
47.2%, respectively). Many of research subjects were
overweight to obese (63%) with a median value of 26.30
(min-max 18.36 – 42.58). More than half of the patients
took the metformin-glimepiride combination (52%)
and took more than 4 tablets a day (70.9%). Patients
suffering from DM for more than 5 years were 46.5%.
The majority of patients had comorbid of hypertension
(63%) and dyslipidemia (63.8%). One patient might have
two comorbids of hypertension as well as dyslipidemia.
Characteristics of patients as research subjects are shown
in Table 1.
Table 1. Characteristics of research subjects
Variable
Sex
Male
Female
Age
Mean ± SD
≤65 years
>65 years
Education level
>12 years
≤12 years
Body Mass Index (BMI)
Median (min – max)
Thin – Normal
Overweight – Obesity
Duration of DM
≤5 years
>5 years
Number of pills prescribed
1-4
>4
OAH agent
Metformin
Metformin-Glimepiride
Others
Cognitive function
Declined
Normal
Comorbidity
Hypertension
Dyslipidemia

Total (N=127)
n (%)
31 (24.4)
96 (75.6)
58.69 ± 8.08
95 (74.8)
32 (25.2)
67 (52.8)
60 (47.2)
26.30 (18.36 – 42.58)
47 (37.0)
80 (63.0)
68 (53.5)
59 (46.5)
37 (29.1)
90 (70.9)
50 (39.4)
66 (52.0)
11 (8.7)
78 (61.4)
49 (38.6)
80 (63.0)
81 (63.8)

Abbreviations: DM, Diabetes Mellitus; OAH, Oral Antihyperglycemic;
BMI, Body Mass Index
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Table 2. Proportion of adherence and nonadherence
based on ARMS and PDC
Adherence
measurement
tools
ARMS
PDC

Nonadhere
n (%)

Adhere
n (%)

77 (60.6)
29 (22.8)

50 (39.4)
98 (77.2)

Abbreviations: ARMS, Adherence to Refills and Medication Scale;
PDC, Proportion of Days Covered

In Table 2, it can be seen that the majority of adhere
patients were 39.4% and 77.2% for ARMS and PDC
respectively. The proportion of adhered patients with
HbA1c<7 were different between methods, which were
40.0% and 29.6% for ARMS and PDC respectively.
Medication adherence measured by ARMS questionnaire
was associated with HbA1c levels with OR 4.000 (95%
CI 1.705 – 9.386), p-value 0.002, as well as PDC with
OR 5.674 (95% CI 1.266 – 25.438), p-value 0.024 (Table
3). To observe the effect of medication adherence and
confounding variables on HbA1c levels, a multivariate
analysis was performed using logistic regression.
Bivariate analysis was conducted to select variables that
had p<0.25 which were gender, age, education level,
type of oral antihyperglycemic drug, and comorbid
hypertension (Table 4). BMI was still included in the
multivariate analysis because it substantially had an
effect on HbA1c. The last multivariate model was
chosen based on the smallest precision value among all
controlled covariates. Table 5 shows the last model of
multivariate; the effect of adherence to HbA1c remained
significant after controlling for hypertension (Table 5).
DISCUSSION
This research found two important things. First, there
was significant association between adherence and
HbA1c levels even after controlling covariates. Second,
ARMS and PDC produce different proportions of adhere
and nonadhere patients yet both significantly associated
with HbA1c levels. The significant association between

adherence and HbA1c is important to ensure effect of
oral antihyperglycemic agents to clinical outcome.
Meanwhile, the contradictive proportion that was created
by two measurement methods indicate that one tool may
not be accurate enough to measure adherence.
This study is in line with study in Qatar showing that
non-adhere patients based on ARMS-D had significantly
higher HbA1c (Jaam et al., 2017). Checking for
medication adherence is an important thing to do in
healthcare facilities, one of which is because poor
adherence can make patients receive excessive therapy
from doctors (Yap et al., 2016). For example, when a
patient does not take medication appropriately, the level
of the drug in his/her body becomes below the therapeutic
range. Hence, the drug is not able to lower blood glucose
optimally. This excess blood glucose makes glycemic
control less than optimal. When the patient comes for a
check-up, the uncontrolled blood glucose level prompts
the doctor to increase the dose titration (Yap et al., 2016).
This unnecessary increase in dose may increase the
risk of hypoglycemia, especially if the patient is taking
oral antihyperglycemic agents of the sulfonylurea class
(Sonmez et al., 2020) and in the long term, can accelerate
disease progression and complications (Bazargan et al.,
2017; Hammad et al., 2017).
Multivariate analysis indicated that hypertension may
decrease HbA1c levels. The type of comorbids can
in fact influence HbA1c levels (Luijks et al., 2015).
However, in contrast to our study, hypertension is
supposed to increase HbA1c levels (Mehta et al., 2011).
This conflicting results may be because some physicians
might give special attention to those with comorbids
when planning a therapy so patients achieve better
clinical outcome. It is supported by study in Croatia
stated that the negative association of the number of
comorbidities and HbA1c may be due to physician
inertia in the treatment of T2DM strictly according to
guidelines (Lang & Marković, 2016).

Table 3. Association between medication adherence with HbA1c <7% level
HbA1c level
MA Category
ARMS
Nonadhere (≥12)
Adhere (<12)
PDC
Nonadhere (<80%)
Adhere (≥80%)

<7%
N (%)

≥7%
N (%)

11 (14.3)
20 (40.0)

66 (85.7)
30 (60.0)

2 (6.9)

27 (93.1)

29 (29.6)

69 (70.4)

p-value

OR (95% CI)

0.002*

Ref
4.000 (1.705 – 9.386)
Ref

0.024*

5.674 (1.266 – 25.438)

Abbreviations: *significant, p-value<0,05; Ref, Reference; ARMS, Adherence to Refills and Medications Scale; MA,
Medication Adherence; PDC, Proportion Days Covered
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Table 4. The effect of others independent variable on HbA1c level
Variable
Sex
Male
Female
Age
Mean ± SD
≤65 years
>65 years
Education level
>12 years
≤12 years
Body Mass Index (BMI)
Median (min – max)
Thin – Normal
Overweight – Obesity
Duration of DM
≤5 years
>5 years
Number of pills prescribed
1-4
>4
OAH agent
Metformin
Metformin-Glimepiride
Others
Cognitive function
Declined
Normal
Comorbidity
Hypertension
Dyslipidemia

N=127
HbA1c ≥7
n (%)

HbA1c <7
n (%)

Total
n (%)

19 (19.8)
77 (80.2)

12 (38.7)
19 (61.3)

31 (24.4)
96 (75.6)

57.76 ± 7.74
75 (78.1)
21 (21.9)

61.54 ± 8.56
20 (64.5)
11 (35.5)

58.69 ± 8.08
95 (74.8)
32 (25.2)

46 (47.9)
50 (52.1)

21 (67.7)
10 (32.3)

67 (52.8)
60 (47.2)

p-value

0.059
0.033*
0.201

0.086

26.32 (20.20 – 42.58) 26.14 (18.36 – 36.03) 26.30 (18.36 – 42.58) 0.639
35 (36.5)
12 (38.7)
47 (37.0)
0.991
61 (63.5)
19 (61.3)
80 (63.0)
51 (53.1)
45 (46.9)

17 (54.8)
14 (45.2)

68 (53.5)
59 (46.5)

1.000

27 (28.1)
69 (71.9)

10 (32.3)
21 (67.7)

37 (29.1)
90 (70.9)

0.831

33 (34.4)
57 (59.4)
6 (6.3)

17 (54.8)
9 (29.0)
5 (16.1)

50 (39.4)
66 (52.0)
11 (8.7)

0.010*

56 (58.3)
40 (41.7)

22 (71.0)
9 (29.0)

78 (61.4)
49 (38.6)

0.296

56 (58.3)
64 (77.8)

24 (77.4)
17 (22.2)

80 (63.0)
81 (63.8)

0.089
0.329

Abbreviations: *significant, p-value<0,05; Ref, Reference; DM, Diabetes Mellitus; OAH, Oral Antihyperglycemic; BMI, Body Mass Index

When medication adherence was measured by the
ARMS questionnaire, the majority of research subjects
were non-adhere (77/127). Meanwhile, when medication
adherence was measured by the PDC calculation, the
majority of research subjects were adhere (98/127). This
discrepancies between methods also happened in some
studies (Liu et al., 2001; Llabre et al., 2006; Pandey et
al., 2015; Cain et al., 2020). Evidence showed that high
ARMS scores seem to identify true non-adhere patients
(Okumura et al., 2016). Therefore, the number of nonadhere patients was more than PDC since ARMS is

more sensitive to non-adhere patients. Regardless of the
difference, both adherence that was determined by ARMS
and PDC gave significant association to lower HbA1c
levels with odds ratio of 4 and 5.674, respectively. The
big difference of proportion between HbA1c <7% and
≥7% in non-adhere group, both using ARMS and PDC,
may be the explanation behind this result.
Generally, each method has advantages and
disadvantages. The self-report method with ARMS
questionnaire can provide additional information about
E-ISSN 2477-0612
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Table 5. Factor that influence HbA1c <7%
Model

Variables

p-value

OR

95% CI

0.001

Ref
4.000

1.705-9.386

0.001

Ref
4.281

1.785-10.267

0.044

Ref
2.735

1.027-7.278

0.001

Ref
4.000

1.705-9.386

0.022

Ref
5.83

1.287-26.405

0.057

Ref
2.524

0.972-6.553

ARMS
Crude

Adjusted

Adherence
Nonadhere
Adhere
Adherence
Nonadhere
Adhere
Hypertension
No
Yes

PDC
Crude

Adjusted

Adherence
Nonadhere
Adhere
Adherence
Nonadhere
Adhere
Hypertension
No
Yes

Abbreviations: Ref, Reference; ARMS, Adherence to Refills and Medications Scale; MA, Medication
Adherence; PDC, Proportion Days Covered

attitudes, habits, and intentions (Anghel et al., 2019).
However, it is affected by memory that could generate
biases so reducing accuracy and validity (Al-Hassany
et al., 2019). On the other side, PDC calculation is an
indirect method that requires a centralized electronic
system. This method requires consistency between the
prescription written in the electronic system and the drug
dispensed to the patient (Anghel et al., 2019). This method
is more objective than the self-report method because the
patient is not aware that he/she is being assessed. The
assumption that the refilled medication will be ingested
by the patient is indeed one of the weaknesses of PDC.
Thus, this can create an overestimation of adherence
outcomes (Al-Hassany et al., 2019; Anghel et al., 2019)
as occurred in this research. This study demonstrated
that ARMS gave lower number of adhere patients than
PDC (50 vs. 98 patients). This data was supported by
the fact that the proportion of adhere patients based on
the PDC value was 77.2% (98/127). However, 70.4%
(69/98) of these patients had a level of HbA1c ≥7. This
might be because the patient never actually swallowed
the pill for various reasons such as forgetting (Cain et
al., 2020) or deliberately not willing to take the medicine
for example, worried about side effects (Kvarnström et
al., 2021).
E-ISSN 2477-0612

Despite the potential inaccuracy of PDC, this study used
PDC to confirm the ARMS-based adherence association
to HbA1c level since PDC was older and has been
widely used (Avorn et al., 1998; Benner et al., 2002).
This study found that fourty two out of fifty adhere
patients based on ARMS were also considered adhere
based on PDC. The answers from the remaining eight
patients may be affected by response biases or they
may bought their medications in pharmacies outside the
primary health provider. However, the overlap adherence
classification in the 42 patients may indicate that ARMS
can potentially be a good adherence measurement, not
to mention the significant association between adherence
and HbA1c levels. In addition, the ARMS questionnaire
was significantly correlated with the Morisky adherence
scale (Spearman’s rho = -0.651, p < 0.01) (Kripalani et
al., 2009). Unlike the Morisky scale which only measures
adherence in refilling, the ARMS questionnaire has 2
subscales that evaluate taking the drug and drug refilling
adherence behavior. This is certainly an advantage of
this questionnaire because non-adherence to taking
medication and non-adherence to refill drugs are different
problems. Hence, ARMS can be a good alternative for
measuring adherence.
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The decision about which method to use should be based
on considerations of the route of drug administration,
available resources, setting, and objectives of the
assessment (Nichols et al., 2016). For example, PDC will
be suitable when patients are hard to reach. In contrast,
ARMS will be convenient when pharmacy records are
not reliable. However, the use of two methods might
be better. PDC can confirm patients response regarding
refilling adherence in ARMS questions because refilling
records are provided in a system. Combining two or more
methods in measuring adherence to taking medication is
highly recommended by being able to cover each other’s
shortcomings and obtain results that are close to the
actual condition (Anghel et al., 2019; Al-Hassany et al.,
2019).
Evidence of adherence association to HbA1c levels is
expected to encourage health professionals to eagerly
counsel patients about the importance of adherence. This
result also warn health professionals and patients that
nonadherence prevalence are still common that it needs
special attention. In addition, the choice of adherence
measurement is also a concern to this study. However,
since this study only observed proportion when
comparing adherence measurement methods, further
research is required to analyze the validaty comparison
between variaty of adherence measurement methods and
their association with HbA1c levels in T2DM patients.
LIMITATIONS
This research has some limitations. It was conducted only
at one health center in one city. In addition, the research
uses a cross-sectional study design and the sample size is
still relatively small, thus limiting the statistical power.
Bigger sample size and cohort studies that involve follow
up measurement of HbA1c are necessary to confirm the
present results.
CONCLUSION
Significant association was found between medication
adherence and HbA1c levels even after controlling
covariates. Proportion difference of adhere patients using
ARMS and PDC may indicate that one method may not
be accurate enough to measure adherence.
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